Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Agennix
Agennix gets U.S. FDA orphan drug designation for Talactoferrin Alfa in kidney cancer
November 7th, 2006
Agennix announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's oral formulation of Talactoferrin Alfa (talactoferrin or TLF) for the treatment of renal cell carcinoma (RCC). Oral TLF is currently in phase II clinical development for RCC. Results from a multicenter phase II RCC trial that included six leading U.S. cancer centers were presented at the 2006 annual meeting of the American Society of Clinical Oncology (ASCO). "The phase II results with talactoferrin in RCC are promising," said Eric Jonasch, an oncologist in Genitourinary Medical Oncology at the M.D. Anderson Cancer Center, and a...
Source: Drug Law Weekly (2006-11-07)
|
